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Background: Visceral leishmaniasis (VL), a potentially fatal disease, is most prevalent in the Indian subcontinent,
East Africa and South America. Since the conventional antileishmanial drugs have many limitations we evaluated a
new ergosterol rich liposomal amphotericin B formulation, KALSOME™10 for its leishmanicidal efficacy, tolerability
and immunomodulatory activity.
Methods: Normal healthy mice were treated with 3.5 mg/kg single and 7.5 mg/kg single and double doses of
KALSOME™10. Liver and kidney function tests were performed fourteen days after treatment. Next, normal mice
were infected with Leishmania donovani amastigotes. Two months post infection they were treated with the above
mentioned doses of KALSOME™10 and sacrificed one month after treatment for estimation of parasite burden in
the liver and spleen by Limiting Dilution Assay. Leishmanial antigen stimulated splenocyte culture supernatants
were collected for cytokine detection through ELISA. Flow cytometric studies were performed on normal animals
treated with KALSOME™10, Amphotericin B (AmB) and AmBiosome to compare their immunomodulatory activities.
Results: The drug was found to induce no hepato- or nephrotoxicities at the studied doses. Moreover, at all doses,
it led to significant reduction in parasite burden in two month infected BALB/c mice, with 7.5 mg/kg double dose
resulting in almost complete clearance of parasites from both liver and spleen. Interestingly, the drug at 7.5 mg/kg
double dose could almost completely inhibit the secretion of disease promoting cytokines, IL-10 and TGFβ, and
significantly elevate the levels of IFNγ and IL-12, cytokines required for control of the disease. Mice treated with
KALSOME™10 showed elevated levels of IFNγ and suppressed IL-10 secretion from both CD4+ and CD8+ subsets
of T cells, as well as from culture supernatants of splenocytes, compared to that of normal, AmB and AmBisome
treated animals.
Conclusions: Treatment of infected mice with 7.5 mg/kg double dose of KALSOME™10 was safe and effective in
clearing the parasites from the sites of infection. The drug maintains the inherent immunomodulatory activities of
AmB by effectively suppressing disease promoting cytokines IL-10 and TGFβ, thereby boosting IL-12 and IFNγ levels.
This emphasizes KALSOME™10 as a promising drug alternative for lifelong protection from VL.
Keywords: Drug, Liposomal amphotericin B, Leishmania, Efficacy, Toxicity, Immunomodulation, Cytokine,
Immune response* Correspondence: nali@iicb.res.in
1Infectious Diseases and Immunology Division, Indian Institute of Chemical
Biology, 4, Raja SC Mullick Road, Jadavpur, Kolkata 700032, West Bengal, India
Full list of author information is available at the end of the article
© 2015 Asad et al.; licensee Biomed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Asad et al. BMC Infectious Diseases  (2015) 15:188 Page 2 of 12Background
Visceral leishmaniasis (VL) or kala-azar, a disseminated
infection of the lymphoreticular system, is caused by the
protozoan parasite(s) Leishmania donovani and/or L.
infantum/chagasi. An estimate of 0.2-0.4 million global
VL cases are reported each year with more than 90%
of them occurring in India, Bangladesh, Sudan, South
Sudan, Brazil and Ethiopia [1] Human infections can
be asymptomatic or oligosymptomatic with manifestations
including persistent low grade fever, hepatosplenomegaly,
cachexia, pancytopenia and hypergammaglobulinemia.
During active VL the parasites multiply within the macro-
phages of spleen, liver and bone marrow resulting in fatal
outcome if untreated [2]. The course of disease progres-
sion signifies cell-mediated immune response (CMI) to
play an important role in protection or development of
VL [3]. Active VL is characterized by suppression of CMI,
which is apparent from the unresponsiveness of patients
to different delayed type hypersensitivity (DTH) tests
(Leishmanin skin test or Montenegro test) as well as
defective lymphoproliferative response of the peripheral
blood mononuclear cells [4]. Recovery from infection
following an effective chemotherapy, on the other hand, is
associated with a strong cell mediated DTH response [5].
Thus a favorable CMI in response to appropriate treatment
marks the successful cure of VL.
In the absence of a vaccine, chemotherapy is the main-
stay to combat the disease. Until the year 2000, pentava-
lent antimonials (Sbv) were the frontline treatment for
VL. However, with the emergence of antimony resistant
parasites in parts of northern Bihar, India, amphotericin
B (AmB) was introduced which renders high cure rates
(>95%) in VL patients [6]. However, AmB which requires
intravenous administration of long duration is highly
toxic and has frequent adverse effects, including infusion-
related fever and chills, nephrotoxicity, hepatotoxicity and
hypokalemia [7]. To overcome its drawbacks lipid formu-
lations of AmB (L-AmB) have been developed to reduce
organ toxicity as well as treatment duration. Most of these
formulations are, however, exorbitantly costly. Although
WHO has recently reduced the price of one such formula-
tion, AmBisome, the cost of these L-AmBs still precludes
their widespread use in the developing countries [8]. In
this context an Indian formulation of L-AmB, Fungisome
has been introduced. A clinical trial with this drug at
doses of 2 mg/kg for 10 days, 3 mg/kg for 5 days and
3 mg/kg for 7 days yielded cure rates of 100%, 90.9% and
100% respectively [9]. These encouraging results paved
the way for a short-course therapy to determine whether a
relatively larger amount of Fungisome could be safely and
effectively administered at single (5 and 7.5 mg/kg) or
double (5 mg/kg) doses. The treatment regimens mani-
fested a successful cure rate of 50-90% at 6 months post-
treatment. A close look at the immunological profile ofthe VL patients at one week after treatment revealed a sig-
nificant fall in plasma IL-10 levels in all successfully cured
patients. Investigations on the antigen-specific cytokine
production by PBMCs showed an enhanced Th1 type
response with upregulated IFNγ, IL-12 and TNFα and
reduced IL-10 and TGFβ production one week post-
treatment in patients who were successfully cured at
6 months irrespective of the drug-dose [10]. These results
with Fungisome could match the immunological profile
obtained with AmB as early as one week posttreatment
demonstrating the importance of immunomodulatory
effects exerted by the disease inhibiting cytokines for
successful cure [7,10].
Most of the L-AmBs in clinical use contain cholesterol
as one of the constituents and is useful for stability and
targeted delivery of the drug [9,11,12]. Cholesterol, on
the other hand, plays a crucial role in active VL facilitat-
ing the internalization of the parasites [13]. Recent work
of Chandel et al. demonstrates that exogenous choles-
terol, if added in the culture, can enhance the growth of
Leishmania promastigotes [14]. Therefore, after internal-
ization, the cholesterol requirement by Leishmania for
its sustenance may be fulfilled by salvaging cholesterol
from host macrophages. Hence, formulation of liposomal
AmB devoid of cholesterol is a good strategy in designing
antileishmanial drugs. Thus, new amphiphilic L-AmB,
KALSOME™10 has been developed where AmB is in-
tercalated with sterol and phosphatidyl choline. This
is a sterol rich drug where ergosterol constitutes 50%
molarity of total lipid in the liposome [15]. Absence
of cholesterol could make this drug more suitable for
clearing parasites. A recent study with KALSOME™10,
at 7.5 mg/kg triple dose, reported successful therapy
(98.85% amastigote suppression) of BALB/c mice with
established L. donovani infection [16]. Here we have
evaluated lower doses of KALSOME™10 (3.5 mg/kg
single dose, 7.5 mg/kg single dose and 7.5 mg/kg double
dose) for their efficacy in curing murine VL. In addition,
we were interested to investigate whether a similar modu-
lation of cytokine profile as observed with AmB treatment
could be obtained with KALSOME™10 to identify the pos-
sible mechanism of cure. Along with efficacy, tolerability
of these doses was also evaluated through different liver
(SGOT, SGPT and alkaline phosphatase) and kidney (urea
and creatinine) functioning parameters.
Methods
Drug, kits and chemical reagents
KALSOME™10 (formulation code: K10, concentration:
10 mg/ml) was provided by Lifecare Innovations Pvt.
Ltd., Gurgaon, India. Toxicity study kits (SGPT, SGOT,
Alkaline phosphatase, Urea and Creatinine) were purchased
from Randox Molecular Diagnostics, London, UK. ELISA
kits for cytokines IL-10, IL-12 and IFNγ were obtained
Figure 1 Plan of work for efficacy study of KALSOME™10.
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from eBioscience (San Diego, CA, USA). The following
fluorochrome tagged mAbs obtained from BD Pharmin-
gen were used: anti-mouse CD4 PE-Cy7, anti-mouse
CD8a Percp-Cy5.5, IFNγ Alexa fluor 488 and IL-10
APC.
Animals and parasites
BALB/c mice (4–6 weeks old) used in the experiments
were bred in the Institute’s animal house facility. The
studies were performed according to the Committee for
the Purpose of Control and Supervision on Experimental
Animals (CPCSEA), Ministry of Environment and Forest,
Govt. of India, and approved by the animal ethics com-
mittee (147/1999/CPSCEA) of Indian Institute of Chem-
ical Biology. L. donovani strain AG83 (MHOM/IN/1983/
AG83), originally isolated from an Indian kala-azar pa-
tient, was maintained by serial passage in hamsters [17].
Formulation of KALSOME™10
KALSOME™10, a gift from Lifecare Innovations Pvt Ltd,
India is a sterol enriched liposome, intercalating AmB,
in an aqueous suspension. Ergosterol constitutes almost
50% of the total liposomal lipid, overall consisting of
phospatidylcholine, ergosterol and AmB in 5:2:1.8 ratios.
The composition was sonicated during manufacture and
before administration for increasing plasma half-life and
better bio-distribution [15].
In vivo efficacy study
Thirty healthy BALB/c mice (4–6 weeks old) were in-
fected with 2.5 × 107 freshly isolated amastigotes [18].
Six mice were randomly sacrificed after two months to
estimate the parasite burden (liver LDA = 10.65 ± 0.92
and spleen LDA = 8.57 ± 0.54). The rest were divided
randomly into four different experimental groups. One
group was kept as infected control and others were ad-
ministered with 3.5 mg/kg and 7.5 mg/kg single doses
and 7.5 mg/kg double dose of KALSOME™10 respect-
ively dissolved in 200 μl of 0.02 M PBS through the tail
vein (Figure 1).
Determination of parasite burden
One month after treatment all the mice were sacrificed,
spleen and liver were removed aseptically, and parasite
burden of the organs were quantified by Limiting Dilution
Assay (LDA) as described earlier [18]. Briefly weighed
pieces of spleen and liver from experimental mice were
first homogenized in Schneider’s medium supplemented
with 10% FCS, and then diluted to a final concentration
of 1 mg/ml. Five-fold serial dilutions of the homogenized
tissue suspension were plated in 96-well plates and incu-
bated at 22°C. Wells were examined for viable and motile
promastigotes after 15 days and the reciprocal of thehighest dilution positive for parasites was considered as
the parasite concentration per mg of tissue. The total
organ parasite burden was calculated using the weight of
the respective organs. In a separate study BALB/c mice
were infected similarly for two months and treated with
AmB and AmBisome with 2.5 and 3.5 mg/kg AmB
respectively. LDA of liver and spleen was performed as
described above.
In vivo toxicity study
For toxicity study, twenty four healthy adult (8–10 weeks
old) BALB/c mice weighing approximately 25 g were
randomly divided into groups of six mice each. One
group was kept as control and rest were injected with
3.5 mg/kg single dose, 7.5 mg/kg single dose and
7.5 mg/kg double dose of KALSOME™10, respectively, in
200 μl of 0.02 M PBS through the tail vein. Liver (SGPT,
SGOT and alkaline phosphatase) and kidney (urea and
creatinine) toxicity tests were performed 14 days after
drug administration [19] and compared with that of the
control group (Figure 2).
Preparation of leishmanial promastigote membrane
antigen (LAg)
LAg was prepared from L. donovani promastigotes as
described earlier [18]. Briefly, stationary phase promasti-
gotes were washed in PBS (pH 7.2) and resuspended in
5 mM Tris HCl buffer (pH 7.6). The suspension was
vortexed and centrifuged at 2,310 g for 10 min. The
crude ghost membrane pellet was resuspended in the
same buffer and sonicated for 3 min by an ultrasound
probe sonicator (Misonix, Farmingdale, NY). The sus-
pension was centrifuged at 5,910 g for 30 min and the
Figure 2 Plan of work for toxicity study of KALSOME™10.
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use. The amount of protein obtained from a 1.0 g cell
pellet was approximately 24 mg.
Cell proliferation and cytokine assays
For cell proliferation and cytokine assay, spleens were
aseptically removed from normal, infected and treated
animals one month posttreatment. Single cell suspension
was prepared in RPMI 1640 supplemented with 10%
FBS, l00 U/ml penicillin G sodium, 100 μg/ml strepto-
mycin sulfate and 50 μM β-mercaptoethanol. RBCs were
removed by lysis with 0.14 M Tris buffered NH4Cl. The
remaining cells were washed twice in culture medium
and viable mononuclear cell number determined by
counting Trypan blue unstained cells in a hemocytometer.
The cells (1 × 106/ml) were then cultured in duplicate in
96-well flat-bottom tissue culture plates (Nunc) and stim-
ulated with LAg (10 μg/ml) for 3 days at 37°C in 95%
humidified air with 5% CO2 [7]. To compare the immuno-
modulatory activity of KALSOME™10 with that of AmB
and AmBisome, normal BALB/c mice were divided into
eight groups. Group I was kept as healthy control. Groups
II, III and IV were administrated with 3.5 mg/kg single
dose, 7.5 mg/kg single dose and 7.5 mg/kg double dose of,
KALSOME™10, respectively. Group V was given 2.5 mg/
kg AmB and groups VI, VII and VIII were administrated
with 3.5 mg/kg single dose, 7.5 mg/kg single dose and
7.5 mg/kg double dose of, AmBisome, respectively in
200 μl of 0.02 M PBS through the tail vein. Splenocyte
cultures from normal and treated groups of mice were
stimulated with ConA (2.5 μg/ml). For cytokine ana-
lysis, culture supernatants were collected after 72 h
and concentrations of IFNγ, IL-12, TGFβ and IL-10
were estimated by ELISA according to the manufacturer’s
instructions.Flow cytometry
Flow cytometry was performed on various T cell subsets
and the intracellular cytokines produced by these cells
from normal and drug treated mice were analyzed as
described [18]. Splenocytes from different groups of
experimental and healthy mice were stimulated for
12 hours with ConA (2.5 μg/ml). Brefeldin A (10 μg/ml)
was added to the cultures 2 hours before harvesting. The
cells were then washed in FACS buffer (0.02 M PBS and
1% FBS) and stained with fluorescent conjugated surface
markers for CD3, CD4 and CD8. Subsequently, cells were
permeabilized with FACS permeabilizing solution and
washed in FACS buffer containing 0.1% saponin. Then
the cells were stained for cytokines IL-10 and IFNγ
and data were acquired by LSRFortessa flow cytometer
(BD Biosciences) and analyzed through FACS Diva soft-
ware (BD Biosciences).Statistical analysis
All data comparisons were tested for significance by One-
way analysis of variance (ANOVA) and Tukey’s multiple
comparisons using Graph Pad Prism version 5.0 (Graph-
pad Software, v. 5.0, San Diego, CA). Results with p < 0.05
were considered to be statistically significant.Results
Effective clearance of Leishmania parasite by KALSOME™ 10
To estimate the efficacy, low doses of KALSOME™ 10
(3.5 mg/kg single dose, 7.5 mg/kg single dose and
7.5 mg/kg double dose) were injected into 2 months in-
fected BALB/c mice. One month after treatment LDA
was performed to evaluate parasite burden at the sites of
infection i.e. liver and spleen. Treatment with 3.5 mg/kg
and 7.5 mg/kg single doses of KALSOME™ 10 showed a
substantial fall (~3-fold) in parasite levels in these organs
compared to infected controls. Administration of 7.5 mg/
kg double dose, on the other hand, resulted in almost
complete clearance of the parasites from both liver and
spleen (Figure 3A and C). Although all the drug doses
were significantly effective in clearing the parasites from
liver and spleen (P < 0.001), 7.5 mg/kg double dose ap-
peared to be most effective with parasite clearance effi-
ciency significantly higher (P < 0.001) than even 3.5 mg/kg
single dose. The weights of infected liver and spleen also
gradually decreased with increase in drug doses (Figure 3B
and D) when compared with infected controls, although
the difference was not significant. Moreover, the efficacy
of KALSOME™ 10 was comparable to that of AmB and
AmBisome (Figure 3A and C). Treatment of infected mice
with 3.5 mg/kg single dose of KALSOME™ 10 generated
similar efficacy as that with a single dose of 3.5 mg/kg
AmBisome and 2.5 mg/kg AmB when compared in both
liver and spleen.
Figure 3 Efficacy of KALSOME™10 in murine VL. Two month infected animals were treated with 3.5 mg/kg single dose (SD) and 7.5 mg/kg SD and
double doses (DD) of KALSOME™10 in 200 μl of 0.02 M PBS through the tail vein. One month post treatment, LDA was performed for evaluating their
efficacy. Parasite burdens (A and C) and weights (B and D) of liver and spleen show the changes at different doses with normal and infected mice.
Data expressed as means ± SE for six mice per group and are representative of two independent experiments with similar results. ***P < 0.001.
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non-challenged BALB/c mice
To detect any functional abnormality of liver due to
KALSOME™ 10 treatment, the drug was administered
into normal healthy BALB/c mice at three different
doses (3.5 mg/kg single dose, 7.5 mg/kg single dose and
7.5 mg/kg double dose) and SGPT, SGOT and alkaline
phosphatase levels measured at 14 days posttreatment.
Treatment with single drug doses of 3.5 mg/kg and
7.5 mg/kg resulted in comparable levels of SGPT and
alkaline phosphatase whereas administration of 7.5 mg/kg
double dose exhibited minor increase in these parameters
compared to untreated controls (Figure 4A and C). Levels
of SGOT in mice treated with 3.5 mg/kg single dose
remained comparable to normal values (Figure 4B). How-
ever, 7.5 mg/kg single dose and double dose treated mice
exhibited some rise in SGOT levels compared to controls.
These differences, however, were insignificant indicating
no aberration in liver function due to drug administration.
Along with hepatotoxicity, nephrotoxicity is also a major
challenge for a prospective drug candidate against leish-
maniasis. The mean level of creatinine for all the drug
doses was found to be similar (Figure 4E) with a small but
insignificant increase in urea levels at 7.5 mg/kg single
and double doses when compared to untreated controls
(Figure 4D).
KALSOME™ 10 mounts a protective response against VL
by regulating different disease promoting/inhibiting
cytokines
VL is associated with impaired cell mediated immunity
marked by the inability of T cells to proliferate or to
produce IFNγ in response to leishmanial antigens [20].
Recent investigations have reported the ability of these
cells to respond to leishmanial antigens with the produc-
tion IL-10 and TGFβ, the key disease promoting factors
in VL [7,21]. The development of resistance and control
over parasites require the production of IL-12 from antigen
presenting cells and IFNγ from T cells [21]. To investigate
whether KALSOME™ 10 therapy can modulate the disease
promoting immune response to effective immunity, we
carried out a detailed immunoprofiling of leishmanial
antigen stimulated splenocyte culture supernatants of
normal, infected and treated mice. Three month infected
BALB/c mice demonstrated significantly higher levels of
IL-10 (P < 0.001) and TGFβ (P < 0.01) in comparison to
normal mice, whereas there was no change in the levels of
IL-12 and IFNγ when compared to normal controls
(Figure 5A and B). Treatment with KALSOME™ 10 at
3.5 mg/kg single, 7.5 mg/kg single and double doses ex-
hibited varying curing efficacies ranging from 53-100%
(Table 1). Interestingly, however, significant fall in the
levels of IL-10 (P < 0.01) and TGFβ (P < 0.01) was ob-
served in all the groups in comparison to infected mice.Nevertheless, 7.5 mg/kg double dose, which showed the
most effective cure, resulted in almost complete inhib-
ition of both of IL-10 and TGFβ (Figure 5C and D).
Again, KALSOME™ 10 induced significantly (P < 0.001)
higher levels of IL-12 and IFNγ at 7.5 mg/kg double
dose (Figure 5A and B) with 7.5 mg/kg single dose
also promoting significant (P < 0.001) elevation of IFNγ
(Figure 5B) emphasizing immunomodulation from disease
promoting cytokine milieu to a strong IL-12 and IFNγ se-
cretion for effective cure against VL.
KALSOME™ 10 treatment induced protective immunity
correlates with a protective cytokine milieu
To compare the immunomodulatory effects of KAL-
SOME™10 with AmB and AmBisome, we administered 3.5
and 7.5 mg/kg (single and double) doses of KALSOME™10
and AmBisome in groups of normal mice. Another group
was injected with 2.5 mg/kg dose of AmB, the maximum
tolerable dose of this drug, keeping an untreated group as
control. After 10 days the animals were sacrificed and
ConA stimulated splenocytes were cultured for cytokine
ELISA and FACS analysis. In cytokine ELISA study, we
found that IFNγ secretion was significantly high from
7.5 mg/kg double dose of KALSOME™10 treated mice
compared to all other groups (Figure 6A). This elevated
secretion of IFNγ correlated well with the suppression of
IL-10 production by this dose. Similarly, significantly high
frequencies of CD4+ and CD8+ cells producing IFNγ were
observed by 7.5 mg/kg double dose of KALSOME™10
compared to 2.5 mg/kg AmB and all administered doses
of AmBisome (Figure 6C and D). Although IFNγ pro-
duction from CD8+ cells was significantly high in AmB
treated group, the highest production of IFNγ was still
observed by 7.5 mg/kg double dose KALSOME™10 treat-
ment. Significant suppression of IL-10 production was
observed in 2.5 mg/kg dose of AmB and 7.5 mg/kg double
dose of AmBisome (Figure 6B), suppression of IL-10 pro-
duction by CD4+ and CD8+ T cells in 7.5 mg/kg double
dose KALSOME™10 treated group was most prominent
compared to normal (Figure 6E and F). Moreover, lowest
level of IL-10 was detected from CD4+ cells of the same
group, reaching almost baseline.
Discussion
AmB, a polyene macrolide, has emerged as the main
antileishmanial drug following the prevalence of SAG re-
sistant Leishmania strains in India. This drug has proved
to be very effective against VL with a cure rate of almost
100% [22]. However, the toxic effects associated with
AmB administration limits its utility [23]. Several lipid
formulations of AmB especially AmBisome have been
exploited very effectively for reducing its toxic effects
and targeted delivery of AmB against Leishmania infec-
tion [24,25]. Unfortunately these formulations are costly
Figure 4 Toxicity study of KALSOME™10 in normal mice. Healthy BALB/c mice were treated with 3.5 mg/kg SD and 7.5 mg/kg SD and DDs of
KALSOME™10 in 200 μl of 0.02 M PBS through the tail vein. Fourteen days post treatment, liver [SGPT (A), SGOT (B) and Alkaline Phosphatase (C)]
and kidney [urea (D) and creatinine (E)] functioning tests were performed on mice serum and compared with that of healthy controls. Data
represented as means ± SE for six mice per group and are representative of two independent experiments with similar results.
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cost. Furthermore, recent reports of VL relapses and de-
velopment of PKDL after apparent cure with AmBisome[26,27] demonstrate the need to develop new L-AmBs.
In addition to its antileishmanial activities, AmB has been
found to possess immunomodulatory function. Therapy
Figure 5 Immunomodulatory role of KALSOME™10. Two month infected BALB/c mice were treated with 3.5 mg/kg SD and 7.5 mg/kg SD and
DDs of KALSOME™10. Leishmanial antigen stimulated culture supernatants of splenocytes obtained from normal, infected and treated mice were
used for cytokine profiling [IL-12 (A), IFN-γ (B), IL-10 (C) and TGFβ (D)]. Data represented as means ± SE for six mice per group and are representative
of two independent experiments with similar results. *P < 0.05, **P < 0.01, ***P < 0.001.
Table 1 Percent reduction in parasite burden by
KALSOME™10, AmB and AmBisome therapy, estimated
by LDA
Drug Percent reduction in LDA values
Liver Spleen
3.5 mg/kg SD* KALSOME™10 53.02 55.7
7.5 mg/kg SD KALSOME™10 78.1 77.02
7.5 mg/kg DD KALSOME™10 100 94.6
2.5 mg/kg AmB 40.65 57.39
3.5 mg/kg AmBisome 54.78 72.02
Groups of 3–6 infected BALB/c mice were treated with the various doses of
the drugs (KALSOME™10, AmB and AmBisome). After one month, mice were
sacrificed to estimate the parasite burden as described in Methods. Percent
reduction in LDA of liver and spleen was calculated based on that of infected
control. *SD: single Dose; ¶DD: Double Dose.
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and IL-12 in splenocytes of treated mice, and PBMC of
kala-azar patients with reduced IL-4, IL-10 and TGFβ pro-
duction [7,18]. Interestingly AmB could upregulate IFNγ
as well as suppress IL-10 and TGFβ in normal mice sple-
nocytes and human PBMCs suggesting its inherent immu-
nomodulatory activity [7]. AmBisome, on the contrary,
could neither promote Th1 response nor downregulate
Th2 cytokines [18] suggesting a lack in immunomodula-
tory function in this L-AmB, whereas essential for parasite
clearance and prevention of relapse following drug treat-
ment [7]. Therefore the need for an efficient and cost
effective liposomal AmB, for short course treatment of
leishmaniasis, having long-lasting protective effect re-
mains. Herein we investigated the curative efficacy and
immunomodulatory activity of a new liposomal formu-
lation of AmB, KALSOME™10 at single (3.5 mg/kg and
7.5 mg/kg) and double dose (7.5 mg/kg) therapy. While
all the doses led to significant reduction in the parasite bur-
den in the two month infected BALB/c mice, treatment
Figure 6 (See legend on next page.)
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Figure 6 Immunomodulatory role of KALSOME™10 on prophylactic model. Normal healthy mice were treated with different doses of KALSOME™10
(3.5 mg/kg single, 7.5 mg/kg single and double), AmBisome (3.5 mg/kg single, 7.5 mg/kg single and double) and AmB (2.5 mg/kg) in seven different
groups with four mice in each group. One group was kept as normal healthy control. Spleen cells of differently treated animals were isolated 10 days
after treatment, plated aseptically (2.5 × 105 cells/well), and stimulated with Con A (2.5 μg/ml). Levels of ConA-specific IFNγ (A) and IL-10 (B) were
determined after 72 hours of incubation by ELISA. Mean frequencies of CD4+IFNγ+ cells per total CD4+ cells (C), CD8+IFNγ+ cells per total CD8+ cells,
(D) CD4+IL-10+ cells per total CD4+ cells (E) and CD8+IL-10+ cells per total CD8+ cells (F) of ConA stimulated splenocytes were determined by flow
cytometry after 12 hours of incubation. Data represented as means ± SE for four mice per group and are representative of two independent
experiments with similar results. *P < 0.05, **P < 0.01, ***P < 0.001.
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in both liver and spleen. These doses were found to be
safe with no hepatic and renal impairment. Further, as
observed in the therapy with free AmB [7], KALSOME™10
maintained the inherent immunomodulatory efficacy of
the AmB and augmented Th1 immune response by sup-
pressing the disease promoting cytokines, IL-10 and
TGFβ.
Leishmania is unique in having the ability to survive
and multiply within host neutrophils and macrophages.
AmB promotes leishmanicidal activity by virtue of its
high intercalation affinity for ergosterol or its precursor
present on the parasite [28]. It, however, can also inter-
act with the cholesterol present in host cell membrane
inflicting toxicity and functional impairment of the re-
ticuloendothelial system (RES) [29]. In KALSOME™10,
AmB is intercalated with ergosterol which constitutes
50% molarity of the total lipid of the liposome [15].
Mechanism of antileishmanial activity of AmB is based
on its interaction with the sterols present on parasite cell
membrane and the subsequent parasiticidal activity.
There are two sterols of relevance while designing a
drug to treat Leishmania infection. One of them is chol-
esterol, present mostly in human kidney cell membranes
and the other is ergosterol, present in parasite. It is notice-
able that affinity of AmB for ergosterol is aproximatly 8.5
times more than that of cholesterol [30]. For effective
treatment, targeted delivery of high doses of AmB is the
desired strategy. Encapsulating higher amount of AmB in
cholesterol containing liposomes may result in leakage of
AmB from the liposomes to the human tissues and or-
gans. To prevent this cholesterol has been replaced by
ergosterol. This strategy ensures that AmB will not be
released from liposomes until it reaches the target. The
breaking up of the liposomes occurs inside the macro-
phages, residence of Leishmania. Thus ergosterol en-
capsulated AmB has a definite edge over cholesterol
encapsulated AmB due to its slow release and greater
target specificity. Also due to higher affinity of AmB to-
wards ergosterol than cholesterol, greater amount of
AmB can be tightly packed inside the liposome and it
can be targeted to the macrophages more efficiently
[15]. In our study we revaluated the tolerability of
KALSOME™10 at 3.5 mg/kg, 7.5 mg/kg single and doubledoses by assessing different nephro- and hepatotoxic pa-
rameters and found it to be non-toxic at all of these doses.
Since L-AmBs are not entirely free of infusion related
toxicities [22,31] and AmBisome has been reported to
show nephrotoxicity at 5 mg/kg triple dose [22,32] these
results were very encouraging and could provide a new
antileishmanial treatment option.
The parasiticidal efficacy of KALSOME™10, at 7.5 mg/
kg triple dose, has already been established in L. donovani
infected BALB/c mice [16]. Our interest was to determine
whether it could successfully maintain its leishmanicidal
activity at lower doses (3.5 mg/kg single dose, 7.5 mg/kg
single and double doses) lower than the reported one.
Herein we showed that therapy of established murine VL
with increasing doses of KALSOME™10 led to progressive
reduction in the parasite load in the visceral organs with
7.5 mg/kg double dose exhibiting complete parasite clear-
ance in both liver and spleen. Additionally reduction in
parasite load with increasing drug doses correlated with
the decrease in the organ weight synchronizing with pro-
gressive cure. The parasite killing efficiency achieved by
KALSOME™10 at such low doses could be matched only
by very few antileishmanial drugs [33]. While 5 mg/kg
triple dose of AmBisome showed similar efficacy in mur-
ine VL, it required longer treatment duration [34]. Even in
kala-azar patients a similar dose (5 mg/kg/day for 3 days
in a span of 10 days for a total dose of 15 mg/kg) of AmBi-
some was reported to cure only 90% of the patients with
few relapses [35,36]. Thus KALSOME™10 has the poten-
tial to become a successful treatment alternative to the
presently used antileishmanial chemotherapies at doses
that are safe and tolerable.
It is well established that the course of disease pro-
gression following L. donovani infection is modulated by
a range of T cell responses and cytokine network. Exten-
sive studies have identified IL-10 as the major player in
the disease pathology of VL [3]. It can render macro-
phages unresponsive to activation signals and inhibit kill-
ing of amastigotes by downregulating the production of
NO [22]. TGFβ has also been reported to have inhibitory
effects on the action of macrophages and its blockade has
been found to limit parasite replication in host cells [21].
Effective elimination of IL-10 and TGFβ synchronizing
with the upregulation of IFNγ and IL-12 could be key
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been reported that chemotherapy with SAG and AmB
cause downregulation of disease promoting cytokines IL-
10 and TGFβ, leading to enhanced IL-12 and IFNγ levels
correlating with cure [5,7,39]. Herein we also found that
treatment of infected mice with increasing doses of
KALSOME™10 (3.5 mg/kg single dose and 7.5 mg/kg
single and double doses) correlated with the reduction
of both the disease promoting cytokines, IL-10 and TGFβ.
Moreover, IL-10 was completely absent and secretion of
TGFβ was almost negligible at 7.5 mg/kg double dose of
KALSOME™10. Subsequently we observed elevation in
both IL-12 and IFNγ levels in infected mice treated
with 7.5 mg/kg double dose. Treatment with 7.5 mg/
kg double dose effectively suppresses disease promoting
cytokines IL-10 and TGFβ, thereby boosting IL-12 and
IFNγ levels. This immune modulation by KALSOME™10
may be responsible for the almost complete parasite clear-
ance observed by 7.5 mg/kg double dose.
Notably KALSOME™10 showed marked immunomod-
ulatory effect at single and double doses of 7.5 mg/kg by
significantly increasing IFNγ level leading to suppression
of IL-10. Elevated production of IFNγ from CD4+ and
CD8+ T cells in 7.5 mg/kg KALSOME™10 treated groups
led to maximum suppression of IL-10 production from
these cells. Such an elevation of IFNγ was almost absent in
AmBisome at all comparative doses. Although some im-
munomodulatory activity was detected by AmB treatment,
the best results were observed only with KALSOME™10.
Therefore, encapsulation of AmB in our formulation not
only maintains the inherent immunomodulatory effects of
AmB, but also enhances it, which is a prerequisite for long
term protection.
Conclusion
In conclusion, we can say that treatment of L. donovani
infected mice with KALSOME™10 at 7.5 mg/kg double
dose resulted in almost complete parasite clearance from
both liver and spleen without inflicting any liver and kid-
ney toxicity. The decline in parasite number was sup-
ported by a curative immune response with a significant
fall in disease promoting cytokines (IL-10 and TGFβ)
and subsequent increase in protective cytokines (IL-12
and IFNγ). These results with KALSOME™10 at 7.5 mg/
kg double dose could match the immunological profile
obtained with AmB as early as two days posttreatment
without showing any infusion related side effects. How-
ever, the role of KALSOME™10 in prevention of reinfec-
tion after cure and long term protection from VL need
further investigation. Till date KALSOME™10 has only
been used in experimental animals, but when it is mar-
keted its price is expected to be 25% less than AmBi-
some by virtue of its 10 times more AmB associated
with liposome in comparison to AmBisome.Competing interests
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